Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 2Gynecologic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Pancreatic Neoplasms 18Breast Neoplasms 10Stomach Neoplasms 9Ovarian Neoplasms 8Prostatic Neoplasms 7Colorectal Neoplasms 6Cholangiocarcinoma 5Glioma 4Sarcoma 3Neoplasm Metastasis 3Lymphoma, Non-Hodgkin 3Esophageal Neoplasms 3Wilms Tumor 2Triple Negative Breast Neoplasms 2Small Cell Lung Carcinoma 2Rhabdomyosarcoma 2Rhabdoid Tumor 2Osteosarcoma 2Neuroectodermal Tumors, Primitive, Peripheral 2Neuroblastoma 2Medulloblastoma 2Histiocytosis, Langerhans-Cell 2Hepatoblastoma 2Ependymoma 2Endometrial Neoplasms 2Central Nervous System Neoplasms 2Bile Duct Neoplasms 2Xanthogranuloma, Juvenile 1Thrombocytosis 1Sarcoma, Ewing 1

Interventions

pembrolizumab 6Nivolumab 5Magnetic Resonance Spectroscopy 4fludarabine 3Sirolimus 3Radiotherapy 3Methods 3Gemcitabine 3Early Intervention, Educational 3Drug Therapy 3Biopsy 3spartalizumab 2epacadostat 2atezolizumab 2X-Rays 2Topotecan 2Surveys and Questionnaires 2Specimen Handling 2Palliative Care 2Nuclear Medicine Department, Hospital 2Ipilimumab 2Interleukin-2 2Educational Status 2Dasatinib 2Cyclophosphamide 2Carboplatin 2vocimagene amiretrorepvec 1ulixertinib 1trastuzumab biosimilar HLX02 1trametinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma × olaparib × Gastrointestinal × Clear all
NCT03205176 2021-05-06

AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including Lymphomas

AstraZeneca

Phase 1 Completed
49 enrolled
BreastGastrointestinalGenitourinaryGynecologicLymphoid

Breast Neoplasms, Lymphoma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡